We are live on ! Find out more
BLRX

BioLineRX
BLRX

18 hedge funds and large institutions have $16.7M invested in BioLineRX in 2014 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

5% less funds holding

Funds holding: 19 → 18 (-1)

7% less capital invested

Capital invested by funds: $17.9M → $16.7M (-$1.25M)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
18
Holders Change
-1
Holders Change %
-5.26%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$1.46M
2
SM
Sabby Management
Florida
+$248K
3
SM
Senvest Management
New York
+$86.4K
4
BCA
Benchmark Capital Advisors
New York
+$42.6K
5
Renaissance Technologies
Renaissance Technologies
New York
+$35K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$1.67M
2
Jane Street
Jane Street
New York
-$130K
3
Citadel Advisors
Citadel Advisors
Florida
-$72K
4
Deutsche Bank
Deutsche Bank
Germany
-$65.1K
5
PA
Perceptive Advisors
New York
-$27.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$4.2M +$248K +198 +6%
SM
2
Senvest Management
New York
$3.31M +$86.4K +69 +3%
BI
3
BVF Inc
California
$3.12M +$1.46M +1,169 +88%
O
4
OrbiMed
New York
$2.36M – – –
OM
5
Opaleye Management
Massachusetts
$1.35M -$1.67M -1,335 -55%
SFM
6
Sphera Funds Management
Israel
$1.25M – – –
Deutsche Bank
7
Deutsche Bank
Germany
$399K -$65.1K -52 -14%
PA
8
Perceptive Advisors
New York
$345K -$27.5K -22 -7%
Renaissance Technologies
9
Renaissance Technologies
New York
$91K +$35K +28 +62%
BCA
10
Benchmark Capital Advisors
New York
$83K +$42.6K +34 +103%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$37K – – –
NFG
12
Next Financial Group
Texas
$30K +$36.3K +29 New
VKH
13
Virtu KCG Holdings
New York
$25K -$13.8K -11 -35%
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$25K – – –
Morgan Stanley
15
Morgan Stanley
New York
$21K +$1.25K +1 +6%
U
16
UBS
Switzerland
$21K +$15K +12 +240%
Wells Fargo
17
Wells Fargo
California
$2K – – –
Ameriprise
18
Ameriprise
Minnesota
$1K +$1.25K +1 New
Jane Street
19
Jane Street
New York
– -$130K -98 Closed
Citadel Advisors
20
Citadel Advisors
Florida
– -$72K -54 Closed
Citigroup
21
Citigroup
New York
– -$2K -1 Closed

BLRX Hedge Fund Activity: Q2 2014 in Review

18 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2014, worth a combined $16.7M — down 7% from $17.9M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of BLRX and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 7 added.

The largest buyer was BVF Inc, adding an estimated $1.46M. The largest seller was Opaleye Management, cutting an estimated $1.67M.

  • 18 institutional investors held BioLineRX (BLRX) as of Q2 2014, down from 19 in Q1 2014.
  • Funds reported $16.7M of BioLineRX stock for Q2 2014, down 7% quarter-over-quarter.
  • 2 funds opened new BioLineRX positions in Q2 2014 and 3 closed out, a net change of -1 holder.
  • The largest BioLineRX buyer in Q2 2014 was BVF Inc, an estimated $1.46M added.
  • The largest BioLineRX seller in Q2 2014 was Opaleye Management, an estimated $1.67M sold.

Based on aggregated 13F filings for Q2 2014.